Lymphoma Program

Short placeholder heading

New Patient Appointments

The Lymphoma Program is part of the Hematologic Oncology Treatment Center. Our specialists are experienced in providing treatment and care for the many varieties of lymphoid malignancies, including:

Non-Hodgkin lymphomas, such as follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia
Hodgkin lymphoma
B-cell neoplasms
T-cell neoplasms

Your care will involve the best and most advanced treatments currently available, combined with new therapies based on research in our laboratories and elsewhere in the field of lymphoma treatment.

What to Know About Lymphoma

Philippe Armand, MD, PhD, Chief of the Lymphoma Division, explains key information about lymphoma, including available treatments, ongoing advances, current research, and clinical trials.

Our Treatment Approach

Our program offers patients access to a multidisciplinary team of lymphoma experts with extensive experience caring for patients with lymphoid malignancies. This experience is particularly important because of the complexity of this type of cancer: There are more than 70 tumor types, each with a unique natural history and each requiring a different approach to treatment.

We provide comprehensive services to patients with lymphoma, including:

evaluation
second opinions
diagnosis (pathologic)
a personalized treatment plan offering the latest therapies
immunotherapy approaches including checkpoint inhibitors and CAR T-cell therapy
access to clinical trials offering novel therapies
comprehensive bone marrow/stem cell transplantation services
support services
access to complementary therapies through the Leonard P. Zakim Center for Integrated Therapies and Healthy Living
follow-up care, including collaboration with your local (referring) physician

Precision Cancer Medicine

Clinicians at Dana-Farber Brigham Cancer Center are now armed with specialized tests to create a precise "tumor profile" for each patient's cancer. Learn more about precision cancer medicine.

CAR T-cell Therapy for Lymphoma

Yescarta is a CAR T-cell therapy that was approved by the FDA for aggressive, refractory non-Hodgkin lymphoma.

More About This Therapy